Skip to main content


Page 1 of 5

  1. Fatty acid binding protein 3 (FABP3) is a target with clinical relevance and the peptide ligand ACooP has been identified for FABP3 targeting. ACooP is a linear decapeptide containing a free amino and thiol gr...

    Authors: Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J. Airaksinen and Xiang-Guo Li
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:16
  2. Recent advancements in positron emission tomograph (PET) using prostate specific membrane antigen (PSMA)-targeted radiopharmaceuticals have changed the standard of care for prostate cancer patients by providin...

    Authors: David Alexoff, Seok Rye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu and Hank Kung
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:15
  3. Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local ...

    Authors: Fabian Krutzek, Cornelius K. Donat and Sven Stadlbauer
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:14
  4. The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of pept...

    Authors: Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A. Nock, Vladimir Tolmachev, Theodosia Maina and Anna Orlova
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:13
  5. Nanoparticles exhibit distinct behaviours within the body, depending on their physicochemical properties and administration routes. However, in vivo behaviour of poly(lactic-co-glycolic acid) (PLGA) nanoparticles...

    Authors: Seung Ho Baek, Eun-Ha Hwang, Gyeung Haeng Hur, Green Kim, You Jung An, Jae-Hak Park and Jung Joo Hong
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:12
  6. Automated dispensing systems (ADSs) for radiopharmaceuticals have been developed to reduce the radiation exposure of personnel, to improve the accuracy of the dispensed dose and to limit the microbiological co...

    Authors: T. T. Cao, E. A. Aalbersberg, M. M. Geluk-Jonker and J. J. M. A. Hendrikx
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:11
  7. Multidrug resistance-associated protein 1 (MRP1), an energy-dependent efflux pump, is expressed widely in various tissues and contributes to many physiological and pathophysiological processes. 6-Bromo-7-[11C]met...

    Authors: Toshimitsu Okamura, Tatsuya Kikuchi, Masanao Ogawa and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:10
  8. In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology ha...

    Authors: Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L. W. Koolen and Erik de Blois
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:9
  9. Overexpressed in various solid tumors, gastrin-releasing peptide receptor (GRPR) is a promising cancer imaging marker and therapeutic target. Although antagonists are preferable for the development of GRPR-tar...

    Authors: Lei Wang, Hsiou-Ting Kuo, Zhengxing Zhang, Chengcheng Zhang, Chao-Cheng Chen, Devon Chapple, Ryan Wilson, Nadine Colpo, François Bénard and Kuo-Shyan Lin
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:8
  10. The current generation of radiolabeled PSMA-targeting therapeutic agents is limited by prominent salivary gland binding, which results in dose-limiting xerostomia from radiation exposure. JB-1498 is a urea-bas...

    Authors: Steve S. Huang, Frank P. DiFilippo, Daniel J. Lindner and Warren D. Heston
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:7
  11. We aimed to develop a publicly shared computational physiologically based pharmacokinetic (PBPK) model to reliably simulate and analyze radiopharmaceutical therapies (RPTs), including probing of hot-cold ligan...

    Authors: Ali Fele-Paranj, Babak Saboury, Carlos Uribe and Arman Rahmim
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:6
  12. Triple-negative breast cancer (TNBC) is one of the most lethal malignant tumors among women, characterized by high invasiveness, high heterogeneity, and lack of specific therapeutic targets such as estrogen re...

    Authors: Yitian Wu, Tuo li, Xianzhong Zhang, Hongli Jing, Fang Li and Li Huo
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:5
  13. The 18F/19F-isotope exchange method employing P(V)-centered prosthetic groups demonstrates advantages in addressing mild one-step aqueous 18F-labeling of peptides and proteins. However, the molar activity (Am) ac...

    Authors: Xiaoqun Tang, Shengji Lv, Zhaobiao Mou, Xia Liu and Zijing Li
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:4
  14. There are only a handful of true theranostic matched pairs, and in particular the theranostic radiocopper trio 61Cu, 64Cu and 67Cu, for diagnosis and therapy respectively, is a very attractive candidate. In fact,...

    Authors: Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka and Martin Kreller
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:3
  15. Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access to a...

    Authors: Aruna Korde, Marianne Patt, Svetlana V. Selivanova, Andrew M. Scott, Rolf Hesselmann, Oliver Kiss, Natesan Ramamoorthy, Sergio Todde, Sietske M. Rubow, Luther Gwaza, Serge Lyashchenko, Jan Andersson, Brian Hockley, Ravindra Kaslival and Clemens Decristoforo
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:2
  16. Transglutaminase 2 (TGase 2) is a multifunctional protein and has a prominent role in various (patho)physiological processes. In particular, its transamidase activity, which is rather latent under physiologica...

    Authors: Robert Wodtke, Markus Laube, Sandra Hauser, Sebastian Meister, Friedrich-Alexander Ludwig, Steffen Fischer, Klaus Kopka, Jens Pietzsch and Reik Löser
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:1
  17. Silver-111 is a promising β-emitting radioisotope with ideal characteristics for targeted radionuclide therapy and associated single photon emission tomography imaging. Its decay properties closely resemble the ...

    Authors: Marianna Tosato, Andrea Gandini, Steffen Happel, Marine Bas, Antonietta Donzella, Aldo Zenoni, Andrea Salvini, Alberto Andrighetto, Valerio Di Marco and Mattia Asti
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:43
  18. The demand for 68Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE. These...

    Authors: Hemantha Mallapura, Olga Ovdiichuk, Emma Jussing, Tran A. Thuy, Camille Piatkowski, Laurent Tanguy, Charlotte Collet-Defossez, Bengt Långström, Christer Halldin and Sangram Nag
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:42
  19. The Affibody molecule, ABY-025, has demonstrated utility to detect human epidermal growth factor receptor 2 (HER2) in vivo, either radiolabelled with indium-111 (111In) or gallium-68 (68Ga). Using the latter, 68G...

    Authors: Emma Jussing, Mélodie Ferrat, Mohammad M. Moein, Henrik Alfredéen, Tetyana Tegnebratt, Klas Bratteby, Erik Samén, Joachim Feldwisch, Renske Altena, Rimma Axelsson and Thuy A. Tran
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:41
  20. Heterometallic gold metallacages are of great interest for the incorporation of several cations. Especially in nuclear medicine, those metallacages can serve as a platform for radionuclides relevant for imagin...

    Authors: Anna Baitullina, Guilhem Claude, Suelen F. Sucena, Eda Nisli, Cedric Scholz, Punita Bhardwaj, Holger Amthauer, Winfried Brenner, Christopher Geppert, Christian Gorges, Ulrich Abram, Pedro Ivo da Silva Maia and Sarah Spreckelmeyer
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:40
  21. The International Atomic Energy Agency (IAEA) held the 3rd International Symposium on Trends in Radiopharmaceuticals, (ISTR-2023) at IAEA Headquarters in Vienna, Austria, during the week of 16–21 April 2023. T...

    Authors: Amirreza Jalilian, Clemens Decristoforo, Melissa Denecke, Philip H. Elsinga, Cornelia Hoehr, Aruna Korde, Suzanne E. Lapi and Peter J. H. Scott
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:39
  22. The alpha-emitter radium-223 (223Ra) is presently used in nuclear medicine for the palliative treatment of bone metastases from castration-resistant prostate cancer. This application arises from its advantageous ...

    Authors: Sara Franchi, Mattia Asti, Valerio Di Marco and Marianna Tosato
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:38
  23. 177Lu-radiopharmaceuticals can contain the metastable impurity [177mLu]lutetium with a physical half-life of 160.4 days, in varying concentrations depending on the route of production of the radionuclidic precurs...

    Authors: Matthias Balzer, Fleur Spiecker, Stephanie Bluemel, Holger Amthauer, Winfried Brenner and Sarah Spreckelmeyer
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:37
  24. The non-invasive imaging of leukocyte trafficking to assess inflammatory areas and monitor immunotherapy is currently generating great interest. There is a need to develop more robust cell labelling and imagin...

    Authors: Maryke Kahts, Hua Guo, Harikrishna Kommidi, Yanping Yang, Haluk Burcak Sayman, Beverley Summers, Richard Ting, Jan Rijn Zeevaart, Mike Sathekge and Omer Aras
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:36
  25. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Jean DaSilva, Clemens Decristoforo, Robert H. Mach, Guy Bormans, Giuseppe Carlucci, Mohammed Al-Qahtani, Adriano Duatti, Antony D. Gee, Wiktor Szymanski, Sietske Rubow, Jeroen Hendrikx, Xing Yang, Hongmei Jia, Junbo Zhang, Peter Caravan, Hua Yang…
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:35
  26. The aim of this brief communication is to highlight the potential bacteriological risk linked to the processes control of radiopharmaceutical preparations made in a radiopharmacy laboratory. Survival rate of Pseu...

    Authors: Julien Leenhardt, Luc Choisnard, Maelle Plasse, Valérie Ardisson, Nicolas de Leiris, Loic Djaileb, Pierrick Bedouch and Marie-Dominique Brunet
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:34
  27. Reduced expression or impaired signalling of tropomyosin receptor kinases (Trk receptors) are found in a vast spectrum of CNS disorders. [18F]TRACK is the first PET radioligand for TrkB/C with proven in vivo brai...

    Authors: Alexander Thiel, Alexey Kostikov, Hailey Ahn, Youstina Daoud, Jean-Paul Soucy, Stephan Blinder, Carolin Jaworski, Carmen Wängler, Björn Wängler, Freimut Juengling, Shirin A. Enger and Ralf Schirrmacher
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:33
  28. Despite the development of positron emission tomography (PET), single photon emission computed tomography (SPECT) still accounts for around 80% of all examinations performed in nuclear medicine departments. Th...

    Authors: Julien Leenhardt, Alexandre Biguet Petit Jean, Florian Raes, Emilien N’Guessan, Marlène Debiossat, Clémence André, Sandrine Bacot, Mitra Ahmadi, Nicolas de Leiris, Loïc Djaileb, Catherine Ghezzi, Marie-Dominique Brunet, Alexis Broisat, Pascale Perret and Amaury du Moulinet d’Hardemare
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:32
  29. Receptor interacting protein kinase 1 (RIPK1) is a serine/threonine kinase, which regulates programmed cell death and inflammation. Recently, the involvement of RIPK1 in the pathophysiology of Alzheimer’s dise...

    Authors: Hiroshi Ikenuma, Aya Ogata, Hiroko Koyama, Bin Ji, Hideki Ishii, Takashi Yamada, Junichiro Abe, Chie Seki, Yuji Nagai, Masanori Ichise, Takafumi Minamimoto, Makoto Higuchi, Ming-Rong Zhang, Takashi Kato, Kengo Ito, Masaaki Suzuki…
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:31
  30. c-MET is a transmembrane receptor involved in many biological processes and contributes to cell proliferation and migration during cancer invasion process. Its expression is measured by immunehistochemistry on...

    Authors: Timofei Rusu, Matthieu Delion, Charlotte Pirot, Amaury Blin, Anita Rodenas, Jean-Noël Talbot, Nicolas Veran, Christophe Portal, Françoise Montravers, Jacques Cadranel and Aurélie Prignon
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:30
  31. Radiopharmaceuticals capable of targeting the fibroblast activation protein have become widely utilized in the research realm as well as show great promise to be commercialized; with [68Ga]Ga-FAPI-46 being one of...

    Authors: Adam J. Rosenberg, Yiu-Yin Cheung, Fei Liu, Carina Sollert, Todd E. Peterson and Jonathan A. Kropski
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:29
  32. In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catal...

    Authors: Maija Radzina, Laura Saule, Edgars Mamis, Ulli Koester, Thomas Elias Cocolios, Elina Pajuste, Marika Kalnina, Kristaps Palskis, Zoe Sawitzki, Zeynep Talip, Mikael Jensen, Charlotte Duchemin, Kirsten Leufgen and Thierry Stora
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:27
  33. In radionuclide therapy, to enhance therapeutic efficacy, an intriguing alternative is to ensure the simultaneous implementation of low- and high-LET radiation emitted from a one radionuclide. In the present s...

    Authors: Nasrin Abbasi Gharibkandi, Kamil Wawrowicz, Agnieszka Majkowska-Pilip, Kinga Żelechowska-Matysiak, Mateusz Wierzbicki and Aleksander Bilewicz
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:26
  34. The positron emitting isotope fluorine-18 (18F) possesses almost ideal physicochemical properties for the development of radiotracers for diagnostic molecular imaging employing positron emission tomography (PET)....

    Authors: Simon Blok, Carmen Wängler, Peter Bartenstein, Klaus Jurkschat, Ralf Schirrmacher and Simon Lindner
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:25
  35. Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain. Radioimmunothe...

    Authors: Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan and Raymond M. Reilly
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:24
  36. Platelet-derived growth factor receptor beta (PDGFRβ) is a receptor overexpressed on activated hepatic stellate cells (aHSCs). Positron emission tomography (PET) imaging of PDGFRβ could potentially allow the q...

    Authors: Olivia Wegrzyniak, Bo Zhang, Johanna Rokka, Maria Rosestedt, Bogdan Mitran, Pierre Cheung, Emmi Puuvuori, Sofie Ingvast, Jonas Persson, Helena Nordström, John Löfblom, Fredrik Pontén, Fredrik Y. Frejd, Olle Korsgren, Jonas Eriksson and Olof Eriksson
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:23
  37. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy which may benefit from radioimmunotherapy. Previously, [177Lu]Lu-DOTA-C595 has been developed as a beta-emitting radioimmunoconjugate to target ...

    Authors: Ashleigh Hull, William Hsieh, Artem Borysenko, William Tieu, Dylan Bartholomeusz and Eva Bezak
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:22
  38. Peptidic radiotracers are preferentially excreted through the kidneys, which often results in high persistent renal retention of radioactivity, limiting or even preventing therapeutic clinical translation of t...

    Authors: Belinda Trachsel, Giulia Valpreda, Alexandra Lutz, Roger Schibli, Linjing Mu and Martin Béhé
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:21
  39. Imaging of cell death can provide an early indication of treatment response in cancer. [99mTc]Tc-Duramycin is a small-peptide SPECT tracer that recognizes both apoptotic and necrotic cells by binding to phosphati...

    Authors: Taco Metelerkamp Cappenberg, Stijn De Schepper, Christel Vangestel, Stef De Lombaerde, Leonie wyffels, Tim Van den Wyngaert, Jeffrey Mattis, Brian Gray, Koon Pak, Sigrid Stroobants and Filipe Elvas
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:20
  40. The liver is a common site for metastatic disease for a variety of cancers, including colorectal cancer. Both primary and secondary liver tumors are supplied through the hepatic artery while the healthy liver ...

    Authors: Anders Josefsson, Angel G. Cortez, Harikrishnan Rajkumar, Joseph D. Latoche, Ambika P. Jaswal, Kathryn E. Day, Mohammadreza Zarisfi, Lora H. Rigatti, Ziyu Huang and Jessie R. Nedrow
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:19
  41. Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radio...

    Authors: Ashleigh Hull, William Hsieh, William Tieu, Dylan Bartholomeusz, Yanrui Li and Eva Bezak
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:18
  42. A family of BF2-chelated tetraaryl-azadipyrromethenes was developed as non-porphyrin photosensitizers for photodynamic therapy. Among the developed photosensitizers, ADPM06 exhibited excellent photochemical and p...

    Authors: Kazunori Kawamura, Tomoteru Yamasaki, Masayuki Fujinaga, Tomomi Kokufuta, Yiding Zhang, Wakana Mori, Yusuke Kurihara, Masanao Ogawa, Kaito Tsukagoe, Nobuki Nengaki and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:14
  43. The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could ...

    Authors: Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois and Yann Seimbille
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:13
  44. Ketones are increasingly recognized as an important and possibly oxygen sparing source of energy in vital organs such as the heart, the brain and the kidneys. Drug treatments, dietary regimens and oral ketone ...

    Authors: Thien Vinh Luong, Erik Nguyen Nielsen, Lise Falborg, Mette Louise Gram Kjærulff, Lars Poulsen Tolbod, Esben Søndergaard, Niels Møller, Ole Lajord Munk and Lars Christian Gormsen
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:12
  45. 177Lu-radiopharmaceuticals are routinely used for the treatment of various tumor entities. The productions of radiopharmaceuticals follow strict good-manufacturing practice guidelines and synthesis optimizations ...

    Authors: Aylin Cankaya, Matthias Balzer, Holger Amthauer, Winfried Brenner and Sarah Spreckelmeyer
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:10

EJNMMI Reports - Kindly explore our collections here

Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at:

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany

CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany

EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.

Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.